Lv2
120 积分 2021-09-23 加入
Deulorlatinib (TGRX-326) in ALK Gene Fusion Positive NSCLC After Failure of Second-Generation Inhibitors: A Single-Arm, Multicenter, Phase 2 Trial
7天前
已完结
Efficacy and safety of ensartinib in the treatment of non-small cell lung cancer: A systematic review of clinical trials
7天前
已完结
Too Old for Surgery? A Case Report of an Octogenarian Patient With Locally Advanced Lung Cancer Achieving Long‐Term Survival via Bilobectomy Followed by Adjuvant Targeted Therapy
22天前
已完结
Sequential EGFR T790M , MET c. 3010C >G‐Associated Exon 14 Alteration, and RET ‐ CCDC6 Fusion in EGFR ‐Mutant NSCLC : A Case Report
1个月前
已完结
Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
1个月前
已完结
Pulmonary langerhans cell histiocytosis following resection of lung adenocarcinoma: a case report and diagnostic challenges
3个月前
已关闭
Ivonescimab monotherapy in an elderly patient with EGFR-TKI-resistant advanced lung adenocarcinoma and pericardial effusion: a case report and literature review
3个月前
已关闭
A novel HEAT repeat protein 5B anaplastic lymphoma kinase fusion in lung adenocarcinoma confers sensitivity to ensartinib
4个月前
已关闭
Thoracic radiotherapy synergizes with first‐line EGFR ‐ TKIs in advanced EGFR ‐mutant NSCLC : A dual‐center real‐world study
5个月前
已完结
Breaking resistance barriers: ensartinib as a milestone in anaplastic lymphoma kinase–driven non-small cell lung cancer therapy
6个月前
已完结
皖公网安备34019202002308
